

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, H, ϕ . Box 1459, Alexandria, VA 22313-1450, d. Box 1450, Alexandria, on the below date:

Date: March 18, 2005 Name: Magdalena O, Cilella, Ph.D.

BRINKS HOFER GILSON &LIONE

Examiner: Not yet assigned

Art Unit: 1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re App	ln. of: '	Wei et al	
-----------	-----------	-----------	--

Appln. No.:

10/630,180`

Filed:

July 30, 2003

For:

METHOD FOR MULTIPLE CHEMOKINE

RECEPTOR SCREENING FOR ANTAGONISTS USING RAM ASSAY

Attorney Docket No:

10709/47

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

	-	-			
Att:	ach	\sim	iel	21	ο.

\boxtimes	Second Supplemental Information Disclosure Sta	atement (in duplicate).
-------------	--	-------------------------

 \boxtimes PTO Form 1449 with copy of cited reference C1.

 \boxtimes Return Receipt Postcard.

Fee calculation:

 \boxtimes No additional fee is required.

П	An extension fee in an amount of \$	for a	-month extension of time under 37 C.F.R. § 1.136(a١

					Sma	II Entity		Not a S	mall Entity
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$9=			x \$18=	
Indep.		Minus			x 43=			x \$86=	
First Pre	esentation of Multiple D	ep. Clain	1		+\$145=			+ \$290=	
					Total	\$		Total	\$

Fee	payment:	
-----	----------	--

A check in the amount of \$ to cover the above-identified fee(s) is enclosed.
Please charge Deposit Account No. 23-1925 in the amount of \$. A copy of this Transmittal is enclosed for this purpose.
Payment by credit card in the amount of \$ (Form PTO-2038 is attached).
The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including an extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Magdalena O. Cilella, Ph.D Registration No. 56,619

Respectfully submitted,



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 18, 2005

Date of Deposit

Magdalena O. Cilella, Ph.D.

Name of Applicant, Assignee or Registered Representative

Signature

March 18, 2005

Date of Signature

Our Case No.: 10709/47

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wei et al.

Examiner:

Serial No.: 10/630,180

Group Art Unit No.: 1645

Filing Date: July 30, 2003

For:

METHOD FOR MULTIPLE

CHEMOKINE RECEPTOR

SCREENING FOR ANTAGONISTS

USING RAM ASSAY

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Second Supplemental Information Disclosure Statement be entered and the document listed below and on the attached Form PTO-1449 be considered by

the Examiner and made of record. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

The reference now cited is the following:

Other Art:

Loetscher et al., "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*", J Biol Chem 2001, 276(5):2986-91.

In accordance with 37 C.F.R. § 1.97(g),(h), this Second Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Second Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this First Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application is a continuation-in-part application of U.S. Serial No. 10/154,399, filed May 22, 2002 and is relied upon for an earlier filing dated under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of documents not previously cited and submitted to the Patent and Trademark Office in the prior application Serial No. 10/154,399 are enclosed for the convenience of the Examiner.

Applicant(s) respectfully request that the listed document be made of record in the present case.

Respectfully submitted,

3/18/05

Magdalena O. Cilella, Ph.D. Registration No. 56,619
Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

CORMERNO-1449	SERIAL NO.	CASE NO.
TABLE .	10/630,180	10709/47
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE		
STATEMENT	July 30, 2003	1645
(use several sheets if necessary)	APPLICANTS: Wei, et al.	

REFERENCE [DESIGNATION	U.S. PATENT DO	CUMENTS		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS EXAMINER | DOCUMENT | CLASS/ TRANSLATION | INITIAL | NUMBER | DATE | COUNTRY | SUBCLASS | YES | NO

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)					
	C1	Loetscher et al., "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*", J Biol Chem 2001, 276(5):2986-91.					

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.